Quest Diagnostics (NYSE: DGX) reported Q2 EPS of $1.55, $0.13 better than the analyst estimate of $1.42. Revenue for the quarter came in at $1.94 billion versus the consensus estimate of $1.94 billion.

"We turned in another strong quarter and are delivering on all five elements of our strategy to accelerate growth," said Steve Rusckowski, Chairman, President and CEO. "We built on our leadership position in advanced diagnostics with our recently-completed acquisition of Med Fusion and ClearPoint. We're expanding on our strategy of being the consumer-friendly provider of diagnostic information services through our growing presence in Safeway stores and now our innovative relationship with Walmart. Based on our progress in the first half we have raised our outlook and are well-positioned to meet our expectations for the rest of the year."

GUIDANCE:

Quest Diagnostics raises FY2017 EPS to $5.62-$5.72, versus $5.45-$560. Quest Diagnostics sees FY2017 revenue of $7.69-7.74 billion, versus prior of $7.64-$7.72 billion.

For earnings history and earnings-related data on Quest Diagnostics (DGX) click here.